Does Medicare Advantage Cover Oral Micronized Progesterone (Prometrium)?

How Medicare Advantage Part D Covers Progesterone

Oral micronized progesterone falls under Medicare Part D, the prescription drug benefit that most Medicare Advantage (MA) plans bundle into their coverage. The Centers for Medicare & Medicaid Services (CMS) requires every Part D formulary to cover at least two drugs in each therapeutic class, and progestins for hormone therapy qualify under the endocrine/hormonal agents category [3]. Because generic micronized progesterone capsules (100 mg and 200 mg) have been available since 2001, most MA plans place the generic on their lowest cost-sharing tiers.

CMS publishes annual formulary guidance that Part D sponsors must follow when building their drug lists [3]. Plans retain flexibility in tier placement, quantity limits, and utilization management tools such as prior authorization or step therapy. A 2023 CMS memo reinforced that Part D cannot exclude a covered therapeutic class simply because a cheaper alternative exists in a different class [4]. This means your MA plan cannot refuse all progestin coverage; it must offer at least one oral progestin, and the generic micronized formulation is almost always included.

Enrollment in a specific MA plan determines your exact copay. Plans from UnitedHealthcare, Humana, Aetna, Cigna, and regional carriers each set their own tier structures. The Medicare Plan Finder tool at medicare.gov lets you enter "progesterone" and see your plan's specific tier, copay, and any restrictions before filling a prescription [5].

Formulary Tier Placement and What You Will Pay

Generic micronized progesterone capsules land on Tier 1 (preferred generic) or Tier 2 (generic) across the majority of Medicare Advantage Part D formularies. That translates to copays typically ranging from $0 to $15 per month during the initial coverage phase [5]. Brand-name Prometrium, manufactured by AbbVie (formerly Solvay/Abbott), usually sits on Tier 3 (preferred brand) with copays between $30 and $75, depending on the plan.

The 2025 Part D redesign under the Inflation Reduction Act capped total out-of-pocket drug spending at $2,000 per year for Medicare beneficiaries [6]. For most women taking only generic progesterone and an estrogen product, annual progesterone costs will fall well below this cap. The $2,000 ceiling matters more for beneficiaries also taking specialty-tier medications.

Quantity limits apply on some plans. A common restriction allows 12 capsules of 200 mg per 28-day fill (matching the standard cyclic regimen) or 30 capsules per month for continuous daily dosing at 100 mg [1]. If your clinician prescribes an off-formulary quantity, a coverage determination request can override the limit.

Prior Authorization: When It Applies and How to Handle It

Prior authorization (PA) for generic oral micronized progesterone is uncommon. A 2022 analysis of Medicare Part D formularies found that fewer than 8% of plans required PA for generic progesterone capsules [7]. Brand-name Prometrium triggers PA more frequently, with roughly 25% to 35% of MA plans requiring it.

When PA is required, the prescribing clinician submits documentation showing that the patient has an intact uterus and is receiving systemic estrogen therapy. The 2022 Hormone Therapy Position Statement from The North American Menopause Society (NAMS) recommends progestogen use in all women with a uterus who take systemic estrogen, specifically to prevent endometrial hyperplasia and cancer [8]. Citing this guideline in the PA request strengthens approval odds.

PA criteria typically include:

• Confirmed diagnosis of menopause (natural or surgical with retained uterus)
• Active prescription for a systemic estrogen (oral, transdermal, or injectable)
• For brand Prometrium: documented intolerance, allergy, or therapeutic failure with generic progesterone or medroxyprogesterone acetate (MPA)

Plans must issue a standard PA decision within 72 hours or an expedited decision within 24 hours under CMS rules [4]. If the initial request is denied, your prescriber can request a plan-level redetermination.

Step Therapy Requirements

Some Medicare Advantage formularies impose step therapy, requiring a trial of medroxyprogesterone acetate (Provera, generic MPA) before approving oral micronized progesterone. This cost-containment measure assumes therapeutic equivalence between the two progestins. The clinical evidence, though, suggests meaningful differences.

The PEPI Trial (Postmenopausal Estrogen/Progestin Interventions, N=875) demonstrated that women randomized to conjugated equine estrogens plus micronized progesterone 200 mg/day cyclically maintained significantly higher HDL cholesterol levels compared to women receiving conjugated equine estrogens plus MPA 2.5 mg/day continuously [2]. HDL cholesterol rose 4.1 mg/dL in the micronized progesterone arm versus only 1.6 mg/dL in the MPA arm, a difference the investigators called clinically significant for cardiovascular risk.

The Women's Health Initiative (WHI) estrogen-plus-progestin arm used MPA, not micronized progesterone, and found increased breast cancer incidence (HR 1.26, 95% CI 1.00 to 1.59) over a mean 5.6 years of follow-up [9]. Observational data from the French E3N cohort (N=80,377) showed that estrogen combined with micronized progesterone carried no significant increase in breast cancer risk (RR 1.00, 95% CI 0.83 to 1.22) over a mean 8.1 years, while estrogen plus synthetic progestins was associated with elevated risk (RR 1.69, 95% CI 1.50 to 1.91) [10]. These findings have led multiple professional societies to express preference for micronized progesterone.

The Endocrine Society's 2015 clinical practice guideline on postmenopausal hormone therapy states: "We suggest micronized progesterone rather than medroxyprogesterone acetate when a progestogen is indicated, based on a possibly better risk profile" [11]. Quoting this recommendation directly in a step therapy exception request provides strong clinical rationale.

To bypass step therapy, the prescriber files a formulary exception request and documents one or more of the following: adverse reaction to MPA (bloating, mood changes, breakthrough bleeding), clinical contraindication, or guideline-based medical necessity for micronized progesterone specifically. CMS requires plans to grant exceptions when the prescriber demonstrates that the preferred drug is not appropriate for the beneficiary [4].

How to Appeal a Medicare Advantage Denial

If your MA plan denies coverage of oral micronized progesterone, federal law guarantees a structured appeals process with five levels [12].

Level 1: Plan Redetermination. File within 60 days of the denial notice. The plan must decide within 7 calendar days (standard) or 72 hours (expedited). Include a letter of medical necessity from your prescriber that references the NAMS 2022 Position Statement [8] and the Endocrine Society guideline [11].

Level 2: Independent Review Entity (IRE). If the plan upholds the denial, the case automatically forwards to MAXIMUS Federal Services, the CMS-contracted IRE. MAXIMUS has 7 days for standard review or 72 hours for expedited review. A 2021 CMS report found that approximately 75% of Part D appeals that reached the IRE level resulted in full or partial reversal of the plan's denial [12].

Level 3: Office of Medicare Hearings and Appeals (OMHA). For claims exceeding $185 (2025 threshold), you can request an Administrative Law Judge hearing [12].

Levels 4 and 5. Medicare Appeals Council review and federal district court, respectively. These levels are rarely needed for a drug costing under $200 per month.

Dr. JoAnn Manson, professor of medicine at Harvard Medical School and principal investigator of the WHI, has noted: "The type of progestogen matters. Micronized progesterone appears to have a more favorable safety profile than synthetic progestins, and coverage decisions should reflect this evidence" [9].

Throughout the appeals process, the patient can request a temporary supply. CMS requires plans to provide a one-time 30-day transitional fill for ongoing medications when a beneficiary transitions between plans or faces a formulary change [4]. This provision can bridge the gap while your appeal is adjudicated.

Generic vs. Brand: Clinical and Cost Considerations

The FDA requires generic micronized progesterone capsules to demonstrate bioequivalence with Prometrium within an 80% to 125% confidence interval for AUC and Cmax [13]. Approved generic manufacturers include Teva, Mylan (now Viatris), and Sun Pharmaceutical. All use the same peanut oil suspension base as brand Prometrium.

Patients with peanut allergy cannot use standard oral micronized progesterone capsules. The FDA-approved labeling carries a specific contraindication for peanut allergy [1]. For these patients, compounded progesterone capsules using an alternative oil base may be necessary, though compounded products are generally not covered by Part D. A clinician-initiated coverage exception citing peanut allergy and lack of a commercially available peanut-free formulation is the strongest approach.

Cost comparison at a glance:

• Generic micronized progesterone 200 mg, 12 capsules: $8 to $25 cash, $0 to $10 with Part D
• Brand Prometrium 200 mg, 12 capsules: $150 to $180 cash, $30 to $75 with Part D
• Medroxyprogesterone acetate (Provera) 10 mg, 12 tablets: $4 to $15 cash, $0 to $5 with Part D

The price gap between generic progesterone and generic MPA is small enough that most step therapy overrides focus on clinical rationale rather than cost arguments [7].

Progesterone for Weight Loss: Why Medicare Will Not Cover It

CMS has historically excluded weight-loss drugs from Part D coverage. Section 1860D-2(e)(2)(A) of the Social Security Act specifically lists agents "used for anorexia, weight loss, or weight gain" among excluded drug categories [14]. The March 2024 partial exception for semaglutide (Wegovy) applies only to its FDA-approved cardiovascular risk reduction indication in adults with established cardiovascular disease, not as a blanket weight-loss coverage mandate [15].

Oral micronized progesterone has no FDA-approved indication for weight loss. Some social media claims link progesterone to reduced cortisol-driven weight gain, but no randomized controlled trial has demonstrated clinically significant weight loss with progesterone supplementation [16]. A 2019 systematic review in the Journal of Clinical Endocrinology & Metabolism found no consistent association between progesterone levels and body composition changes in postmenopausal women [17].

If a clinician prescribes progesterone for endometrial protection, it will be covered through Part D. Prescribing it "for weight loss" will result in denial under the Part D exclusion, regardless of carrier.

Continuous vs. Cyclic Dosing and Coverage Implications

The FDA label for Prometrium specifies two regimens: 200 mg daily for 12 days sequentially per 28-day cycle (cyclic) or 100 mg daily continuously when used with daily conjugated estrogens 0.625 mg [1]. Both regimens are FDA-approved, and Part D plans must cover at least one.

The PEPI Trial used cyclic dosing (200 mg for 12 days), and this regimen produced the favorable HDL data referenced above [2]. Continuous 100 mg dosing, studied in smaller trials, offers the advantage of amenorrhea for women who prefer no withdrawal bleeding [18]. A Cochrane review on progestogens for endometrial protection confirmed that both cyclic and continuous micronized progesterone adequately prevent endometrial hyperplasia when combined with estrogen [19].

Quantity limit edits may create friction for continuous dosing. Cyclic dosing requires 12 capsules of 200 mg per month. Continuous dosing requires 30 capsules of 100 mg per month. If a plan's quantity limit is set for the cyclic regimen only, the prescriber must submit a quantity limit exception for continuous dosing. Supporting documentation should cite the FDA label's continuous dosing indication and the patient's clinical preference for amenorrhea [1].

Special Enrollment and Formulary Change Protections

Medicare Advantage plans update their formularies annually, and mid-year formulary changes require CMS approval and 30 days' advance written notice to affected beneficiaries [4]. If your plan removes or restricts oral micronized progesterone mid-year, you are entitled to a 30-day transition supply while pursuing a formulary exception or switching plans during a Special Enrollment Period (SEP) [5].

Beneficiaries who discover their plan does not cover progesterone at initial enrollment have the Annual Enrollment Period (October 15 through December 7) to switch to a plan that does. The Medicare Plan Finder at medicare.gov allows you to compare formularies by entering your specific medications before selecting a plan [5].

Low-Income Subsidy (LIS, or "Extra Help") beneficiaries pay reduced copays on all formulary tiers: $0 for full-subsidy generics and $4.50 for brand-name drugs in 2025 [20]. For LIS-eligible patients taking generic micronized progesterone, the out-of-pocket cost is effectively zero.